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Method of Flucytosine Assay
Blood samples were routinely obtained for assay of flucytosine levels immediately before and 30 minutes to 1 hour after administration of flucytosine as part of general patient management; these assays were not used to delineate the specific pharmacokinetic properties of flucytosine (e.g., volume of distribution, half-life, and area under the concentration curve). In the event of a suspected adverse effect attributable to flucytosine, additional samples were assayed for drug levels and assessed for toxicity. All but one of the assays were performed in the NIH clinical chemistry laboratory with use of a modification [ 10] of the creatinine iminohydrolase assay [11] [12] [13] [14] . In brief, in this assay flucytosine is hydrolyzed in the presence of creatinine iminohydrolase (from Flavobacteriumfilamentosum E. C. 35421; Eastman Kodak, Rochester, NY), and dissolved in 5% bovine albumin and PBS, pH 7. HPLC method showed good agreement: y = 0.98x + 1.34 mg/L, Sy. x = 3.7 mg/L, as analyzed with the Deming debiased regression (n = 37). This assay had good precision, with coefficients of variation of <3% for within-run controls and <6% for between-run controls. A level offlucytosine was considered toxic if it was >100 Ag/mL.
In patients with normal renal function, the initial dosage of flucytosine was 37.5 mg/kg every 6 hours. In patients with a creatinine clearance of <40 mL/minute, the dosage was decreased to 37.5 mg/kg every 12 hours, and in those with a creatinine clearance of<20 mL/minute, the dosage was 37.5 mg/kg every 24 hours or after dialysis when required. In addition, doses of flucytosine were adjusted to maintain serum levels at <100 /ug/mL in all patients. Mean flucytosine levels before and after a dose were calculated at steady state for each patient in this study by summing the serum values and dividing by the total number of serum samples obtained.
Results

Patient Population
Four patients were excluded from analysis: three had been treated with flucytosine for <1 week, and the entire chart of one patient was unavailable for review. There were 17 evaluable patients (9 males and 8 females). Nine had lymphoma, including the lymphoblastic type, three had solid tumors, three had leukemia, and one had aplastic anemia. At the time of diagnosis of the fungal infection, 14 patients were being actively treated with combination chemotherapy regimens, one patient was being treated with single-agent palliative chemotherapy for end-stage breast carcinoma, and two were receiving no chemotherapy.
Microbiology
Candida albicans was the infecting organism in four patients, producing a fasciitis, fungemia, hepatosplenic candidiasis, and combined fungemia and hepatosplenic candidiasis in one patient each (table 1 ). An unidentified Candida species was responsible in four cases-three of hepatosplenic candidiasis and one of fungemia. Torulopsis glabrata and Candida guilliermondii were each responsible for one episode of fungemia. Candida tropicalis was found in two cases of fungemia and in one case of hepatosplenic candidiasis. Cryptococcus neoformans was found in two patients, one with a progressive solitary lung nodule and the other with a pleural effusion and cryptococcemia. Aspergillus species were responsible for two cases of pneumonia.
Indications for Flucytosine Therapy
Of the 17 patients (table 1) 
Safety and Tolerance
Twelve patients were treated with oral flucytosine, and five were treated with the intravenous preparation because of oral endotracheal intubation. Results of assays of flucytosine levels were readily obtainable within 48 hours for all patients. Forty-five paired samples for drug-level determinations were obtained from the 12 patients before and after oral flucytosine administration. There were only slight differences in pre-and post-dose flucytosine levels (figure 1). Differences between pre-and post-dose flucytosine levels after intravenous administration of flucytosine were greater than those after oral administration. Table 2 depicts the profile of toxic reactions attributed by the clinicians caring for the patients, with the mean serum levels of flucytosine before (trough) and after (peak) the dose. No toxicity was attributable to flucytosine in 13 of 17 patients. Only two patients had mean flucytosine levels of > 100 ,Ig/mL during treatment, and neither developed toxic reactions.
Nine of the 17 patients were granulocytopenic at the in- ception of flucytosine therapy. Flucytosine was temporarily discontinued in one of these nine patients because of prolonged granulocytopenia after recent intensive chemotherapy for lymphoblastic lymphoma. The level of flucytosine was determined at an outside laboratory and was not available for review. Flucytosine therapy was later reinstituted and continued for >2 months, with complete resolution of hepatosplenic candidiasis and without further complications.
Eight of the 17 patients were not granulocytopenic at the onset of flucytosine therapy. Flucytosine did not produce granulocytopenia in these eight patients. One of 17 patients developed prolonged thrombocytopenia (table 2) that was attributed to recurrent acute T cell leukemia, septic shock, and consumptive coagulopathy. Nonetheless, flucytosine Stiller et al. [31] , using mice infected intravenously with C. albicans, suggested that resistance of C. albicans to flucytosine is not absolute and that a continuum of susceptibilities exists. These authors grouped C. albicans isolates into four different groups on the basis of susceptibility to flucytosine over a 7-day period. In their experience, in vitro susceptibility of C. albicans correlated with in vivo response to flucytosine. These findings were confirmed by Polak and Dixon [39] , who were able to stratify 40 isolates of C. albicans in a similar fashion. Mice infected with isolates that were most susceptible to flucytosine survived significantly longer than mice infected with isolates that were highly resistant. 
Toxicity of Flucytosine
Flucytosine has been associated with fatal cases of bone marrow aplasia [4, 5] , hepatic necrosis [6] , and enterocolitis [7, 8] . Few series have prospectively determined serum levels of flucytosine and correlated them with the development of potentially fatal toxicity (table 3) . In a small series by Record et al. [64] , levels of flucytosine were > 100 ,g/mL for a prolonged period in both fatal cases. This series [64] , our study, and a multicenter study of antifungal toxicity in the treatment of cryptococcal meningitis conducted by the Mycoses Study Group [52, 93] found that isolated flucytosine levels of > 100 ,g/mL that were quickly corrected by a reduction in dosage were not clearly associated with the development of toxicity. For example, the Mycoses Study Group [52, 93] noted flucytosine toxicity (granulocytopenia, thrombocytopenia, and anemia either singly or in combination; elevated hepatic enzyme levels; or gastrointestinal symptoms) in 23 of 38 patients with serum flucytosine concentrations >100 gg/ mL for >2 weeks and in 15 of 48 patients whose flucytosine levels were maintained at <100 ug/mL (P = .004) (tables 3 and 4).
Several other investigators [48, 49, 59] (table 3) have reported smaller case series of flucytosine toxicity, in which toxicity was seen when flucytosine levels were > 100 ,g/mL.
In a review by Kauffman and Frame, four of 15 patients experienced bone marrow toxicity; all four had flucytosine levels >125 gg/mL [9] (table 3) . Overall, leukopenia and thrombocytopenia have been reported in 6% of patients; gastrointestinal intolerance (mostly nausea and diarrhea) in 6%; and hepatotoxicity with elevated alkaline phosphatase and transaminase levels in 5% [94] .
Myelosuppression and hepatotoxicity in most patients appear to be concentration-dependent, predictable, possibly avoidable with careful maintenance of flucytosine levels at <100 ,g/mL, and reversible with temporary discontinuation of the drug or a reduction in dosage. For example, Stamm et al. [93] reported that bone marrow dyscrasias (granulocytopenia and/or thrombocytopenia) occurred in 12 of 20 patients with flucytosine levels > 100 ,tg/mL as compared with 8 of 65 with flucytosine levels <100 ug/mL (P < .02); hepatoxicity developed in 6 of 7 patients with flucytosine levels 100 Aug/mL as compared with 1 of 78 with flucytosine levels <100 Mg/mL (P < .004). By comparison, the preponderance of patients reported in this current study had mean flucytosine levels <100 ,g/mL or serum levels only transiently elevated to >100 Ig/mL. These patients experienced minimal toxicity attributable to flucytosine.
As the findings of Stamm et al. [93] and our own data indicate, the relationships between flucytosine-induced bone marrow suppression and hepatoxicity are general and not absolute. For example, some series, including our own, have described patients who suffered adverse effects such as hepatotoxicity or eosinophilia that were idiosyncratic and not related to the flucytosine level [ 
Miscellaneous Factors Influencing Toxicity of Flucytosine
Although their influence is controversial, two factors, amphotericin B-induced renal insufficiency and secondary metabolites of flucytosine and gastrointestinal flora, may influence flucytosine toxicity. Determination of serum levels of flucytosine was critical to the management of invasive mycoses in these immunosuppressed patients and broadened the therapeutic window of a potentially toxic compound. The vast majority of serum flucytosine levels were maintained at <100 Ig/mL. Levels exceeding this value were quickly and appropriately corrected by temporarily discontinuing the drug or reducing the dosage. For this reason, the major toxicities reported in earlier literature were averted in this series and the adverse effects encountered herein were easily managed.
Peak serum levels of flucytosine were not found to be significantly greater than trough levels at steady-state in patients treated with the oral preparation ( figure 1) . A 30-minute interval between administration of flucytosine and the withdrawal of a serum sample could explain this observation, presumably because of the more rapid availability of the intravenous preparation. These findings suggest that determining a serum level for orally administered flucytosine 30-60 minutes after a dose may obviate the need for determining a level before a dose, especially during the steady state. In comparison to the different peak and trough levels observed with intravenous administration of flucytosine, the approximation of the times to reach peak and trough levels of the orally administered compound does not appear to have been widely appreciated. A peak level occurring 2 hours after dosing might reveal a delayed absorption, but the differences are unlikely to be significant. As a further marker of the safety of flucytosine when dosage is guided by serum levels, flucytosine did not produce granulocytopenia in any of the eight patients who were not granulocytopenic. Hepatotoxicity with elevated AST, ALT, alkaline phosphatase, and total bilirubin levels was possibly attributable to flucytosine in only one patient (table 2) . However, mean levels in this patient were 34 A#g/mL before and 60.8 #tg/mL after the flucytosine dose (table 1) The bioassay and its several modifications correlate the sizes of zone inhibition around filter disks or wells impregnated with known concentrations of flucytosine and the test serum with the serum concentration of flucytosine. Minimal technical expertise and apparatus are required, permitting widespread use of this method at low cost. However, the bioassay lacks the precision and rapidity necessary for making efficient dose adjustments, and its reproducibility has also been questioned. GLC methods, which require derivatization of flucytosine, and fluorimetric methods have largely been abandoned in favor of HPLC assays using ion-exchange, ion-pair, and reversed-phase columns. These are rapid (<30 minutes), specific, and accurate, permitting dose adjustments in patients with azotemia. The main drawbacks are the cost and technical expertise required.
On the other hand, the creatinine iminohydrolase assay takes advantage of a fortuitous observation that flucytosine, by virtue of a close structural resemblance to creatinine, causes spurious creatinine elevation in sera as measured by the Kodak Ektachem analyzer (Eastman Kodak, Rochester, NY) [113] [114] [115] [116] [117] . Such apparatus is widely available; no additional technical expertise or cost is required; and the results are precise, expedient, and correlate well with results of HPLC methods [ 10, 14] . As a result, this assay is particularly attractive for making serial measurements to monitor druginduced toxicity. In the creatinine iminohydrolase assay as initially described [11, 12] , NH3 diffused through a semipermeable membrane and reacted with a bromphenol blue indicator. In the assay used in this report, the liberation of NH3 is measured as the difference between the spectrophotometric absorbance of the serum sample and a blank control. The creatinine iminohydrolase assay may be positively influenced by the presence of lipids, therefore chylomicronfree serum should be used [10] . Elevated bilirubin concentrations may affect measured flucytosine concentrations positively by a maximum of 10%, but the assay is not affected by the presence of other pyrimidines, amphotericin B, glucose, or elevated creatinine concentrations.
In this series, the results of assays for flucytosine levels were rapidly available and allowed adjustment of the dose. Only two patients (nos. [23] found that levels of flucytosine that were >25 Aug/mL did not contribute further to the prevention of spontaneous emergence of resistance by C. albicans and T. glabrata. The question of whether lower levels offlucytosine may be used without compromising the therapeutic effect of combination therapy remains to be studied. These lower levels may be particularly beneficial in patients with HIV infection, some of whom may not tolerate conventional dosages of flucytosine. Currently, however, in our patient population the peak serum levels of 40-60 ,g/mL appear to provide a reasonable balance of the factors of antifungal activity, toxicity, and prevention of emergence of resistance.
In summary, the use of antibiotics is associated with adverse effects that must be considered during their administration. Fortunately, levels of selected antimicrobial agents can be expediently measured to decrease the ratio of risk to benefit. For example, the aminoglycosides are extremely useful compounds whose nephrotoxicity and ototoxicity are well recognized yet can potentially be avoided by close measurement of drug levels. Similarly, flucytosine can produce severe adverse effects, particularly granulocytopenia, if administered to azotemic patients without monitoring flucytosine levels. Hence, flucytosine should be used only in cases of documented fungal infection and not as a part of a program of prophylactic therapy for patients with granulocytopenia and prolonged fever. Furthermore, in granulocytopenic patients with invasive mycoses, flucytosine should be administered only in combination with amphotericin B. A clear indication for the use of the combination is induction therapy for cryptococcal meningitis. In patients with acute disseminated candidiasis; hepatosplenic candidiasis; candidal endophthalmitis, endocarditis, meningitis, or peritonitis; or invasive candidiasis caused by non-albicans species, addition of flucytosine to amphotericin B should be strongly considered. If the use of flucytosine is restricted to these situations and if renal function and serum flucytosine levels are closely monitored and the latter are maintained between 40 and 60 Ag/ mL, the combination of amphotericin B and flucytosine can be effective and minimally toxic.
